SCHEMBL4055094

SCHEMBL4055094

N#CCCCOc1cccc(-c2nc3ccc(-c4ccccc4)cc3o2)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TLR9 Q9NR96 4/20 0.50
VSIR Q9H7M9 3/20 0.47
MAPT P10636 2/20 0.47
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
GPR119 Q8TDV5 6/20 0.46
TLR7 Q9NYK1 5/20 0.44
TP53 P04637 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
KDM4E B2RXH2 1/20 0.44
ALDH1A1 P00352 1/20 0.44
HPGD P15428 1/20 0.44
TSHR P16473 1/20 0.44
MAPK1 P28482 1/20 0.44
CASP3 P42574 1/20 0.44
RAB9A P51151 1/20 0.44
SENP8 Q96LD8 1/20 0.44
HSD17B10 Q99714 1/20 0.44
SENP7 Q9BQF6 1/20 0.44
SENP6 Q9GZR1 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4059361 0.89 VSIR (0.53) TLR9VSIRMAPTMEN1KMT2A
SCHEMBL4053064 0.88 TLR9 (0.42) TLR9VSIRMAPTGPR119TLR7
SCHEMBL4062354 0.87 TLR9 (0.45) TLR9MAPTMEN1KMT2AGPR119
SCHEMBL13620468 0.85 TLR9 (0.53) TLR9VSIRMAPTMEN1KMT2A
SCHEMBL4053044 0.83 MAPT (0.52) TLR9VSIRMAPTMEN1KMT2A
SCHEMBL4059683 0.78 NPC1 (0.65) VSIRMAPTKMT2AGPR119TP53
SCHEMBL13608739 0.77 TLR9 (0.59) TLR9VSIRGPR119TLR7RAB9A
SCHEMBL13620568 0.77 VSIR (0.56) TLR9VSIRMAPTMEN1KMT2A
SCHEMBL4054393 0.74 VSIR (0.53) TLR9VSIRMAPTMEN1KMT2A
SCHEMBL13608726 0.74 KDM4E (0.39) MAPTMEN1KMT2ATP53SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7622479-B2 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-24 US disclosed
US-7622479-B2 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-24 US disclosed
US-20050101647-A1 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-05-12 US disclosed
EP-1460067-A1 BICYCLIC DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE Takeda Chemical Industries, Ltd. (JP) 2004-09-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050101647-A1 Bicyclic derivative, its production and use ABL1, SRC, PTK2B TLR9 2579/4885VSIR 4618/4885MAPT 4026/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.